



2022 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan
 中華民國血液及骨髓移植學會(TBMT)暨中華民國血液病學會(HST)聯合學術演講年會一日程總表(第一天)

April 23 (Saturday)					
時間/講堂	第 201 會議室	第 401 會議室	第 205 會議室	第 301 會議室	
09:00	中華民國血液病學會暨中華民國血液及骨髓移植學會聯合學術演講年會開幕(請會員直接至各會議室聽講)				
09:00-09:45	Satellite Symposium (1) ^{艾伯維} Moderator: 田蕙芬 Redefine the Treatment Expectation for Frontline Unfit AML Patients <i>Dr. Dan Pollyea (USA)</i>	Satellite Symposium (2) ^{Sanofi} Moderator: 譚傳德 Expanding triplet combination treatment with a new CD38 antibody for relapsed or refractory multiple myeloma <i>Dr. Thomas G. Martin (USA)</i>	Satellite Symposium (3) ^{麒麟} Moderator: 唐季祿 The roles of thrombopoietin-receptor agonists in the treatment of acquired aplastic anemia <i>Prof. Shinji Nakao (Japan)</i>	09:00-09:45	Satellite Symposium (4) ^{DKSH} Moderator: 陳宇欽 Entering a new era in PNH – from evidence to clinical practice <i>Prof. Ilene C. Weitz (USA)</i>
	Keynote Speech (1) – TBMT Moderator: 柯博升 <i>Hemophagocytic Lymphohistiocytosis (HLH) 2022</i> <i>Prof. Kenneth L. McClain (USA)</i>	全體學員請至第 201 會議室聽講			全體學員請至第 201 會議室聽講
10:35-11:20	醫師會員演講(01) No.01-04 Acute Leukemia-1	醫師會員演講(02) No.05-07 Coagulation	醫師會員演講(03) No.08-11 Pediatric hematology	10:35-12:05	護理專題演講 Moderator: 江孟冠&李宜恬 CAR-T Cell Therapy: A Nuts-To-Bolts Overview Of The Revolutionizing Treatment for Pediatric B-Acute Lymphoblastic Leukemia <i>Kathryn Aaronson(USA)</i> & <i>Erica Southworth (USA)</i>
11:20-12:05	醫師會員演講(04) No.12-15 HSCT-1	醫師會員演講(05) No.16-19 Lymphoma-1	醫師會員演講(06) No.20-23 Myeloma		
12:10-13:10	TBMT 會員大會&選舉(含午餐) 頒發年會贊助廠商感謝狀	非 TBMT 會員午餐用餐區	TBMT 會員 請至第 201 會議室參加會員大會	12:10-13:10	TBMT 會員 請至第 201 會議室參加會員大會
13:10-13:55	醫師會員演講(07) No.24-27 HSCT-2	醫師會員演講(08) No.28-31 MPN	醫師會員演講(9) No.32-35 Lymphoma-2	13:10-14:25	護理會員演講(I) No.01-05
13:55-14:40	醫師會員演講(10) No.36-39 Translation research	醫師會員演講(11) No.40-43 BM failure syndrome	醫師會員演講(12) No.44-46 Lymphoma-3	14:25-14:35	Break, Exhibition, and Poster Viewing

April 23 (Saturday)						
時間/講堂	第 201 會議室	第 401 會議室	第 205 會議室	第 301 會議室		
14:40-15:25	Satellite Symposium (5)^{華*} Moderator: 葉士芃	Satellite Symposium (6)^{BMS} Moderator: 滕傑林	Satellite Symposium (7)^{Pfizer} Moderator: 劉益昌	14:40-15:25	Satellite Symposium (8)^{瑞生} Moderator: 姚明	
	Evolving treatments in Graft-Versus-Host Disease <i>Prof. Mohamad Mohty (France)</i>	Treatment considerations and strategies for transplant-ineligible patients with newly diagnosed multiple myeloma <i>Dr. Daryl Tan (UK)</i>	Paradigm shift in fungal and bacterial infection management <i>Prof. Po-Ren Hsueh (Taiwan)</i>		Maximizing Patients Outcome in MCL(Mantle cell lymphoma) <i>Prof. Georg Hess (Germany)</i>	
15:30-18:35	HST-EHA Joint Symposium and Special Lecture	醫師會員請至第 201 會議室聽講	醫師會員請至第 201 會議室聽講	15:30-16:45	護理會員演講(II) No.06-10	
18:35		第一日會議結束			16:45-17:50	護理會員演講(III) No.11-14



2020 Joint Annual Congress of Taiwan Society of Blood and Marrow Transplantation and The Hematology Society of Taiwan
中華民國血液及骨髓移植學會(TBMT)暨中華民國血液病學會(HST)聯合學術演講年會一日程總表(第二天)

April 24 (Sunday)				
時間/講堂	第 201 會議室	第 401 會議室	第 205 會議室	第 301 會議室
08:00-08:45	Satellite Symposium (9) ^{武田} Moderator: 張正雄	Satellite Symposium (10) ^{CSL} Moderator: 王全正	Satellite Symposium (11) ^{拜耳} Moderator: 陳彩雲	Satellite Symposium (12) ^{MSD} Moderator: 王博南
	Latest advances in the classical Hodgkin lymphoma management : the era of novel therapies <i>Dr. Alex Herrera (USA)</i>	Update evidence and clinical application for hematologic malignancy with secondary immunodeficiencies (SID) <i>Prof. Hsin-An Hou (Taiwan)</i>	Evolving treatment landscape in relapse or refractory iNHL with PI3K inhibitor <i>Dr. Matthew J. Matasar (USA)</i>	The Latest Cytomegalovirus Prevention Guideline and the Newest Strategy of Immune Monitoring after Hematopoietic Cell Transplantation Consensus and Clinical Practices from the US <i>Prof. Roy F. Chemaly (USA)</i>
08:50-09:35	Keynote Speech (2) – HST Moderator: 周文堅	全體學員請至第 201 會議室聽講	全體學員請至第 201 會議室聽講	全體學員請至第 201 會議室聽講
	Clonal hematopoiesis and the origins of blood cancers <i>Prof. Benjamin Ebert (USA)</i>			
09:35-09:45	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing
09:45-11:35	Taiwan and Japan Hematology Forum	全體學員請至第 201 會議室聽講	全體學員請至第 201 會議室聽講	全體學員請至第 201 會議室聽講
11:45-12:15	HST 會員大會(含午餐)	HST 會員請至第 201 會議室參加會員大會	HST 會員請至第 201 會議室參加會員大會	HST 會員請至第 201 會議室參加會員大會
12:15-12:50	HST 青年研究發展獎口頭研究計畫內容報告及各項學術獎頒獎	HST 會員請至第 201 會議室聽講及觀禮	HST 會員請至第 201 會議室聽講及觀禮	HST 會員請至第 201 會議室聽講及觀禮
12:50-13:00	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing	Break, Exhibition, and Poster Viewing
13:00-13:45	Satellite Symposium (13) ^{安斯泰來} Moderator: 侯信安	Satellite Symposium (14) ^{樂華醫藥} Moderator: 陳志丞	Satellite Symposium (15) ^{羅氏} Moderator: 柯博升	Satellite Symposium (16) ^{安進} Moderator: 蕭惠祥
	Evolving treatment in AML <i>Prof. Mark James Levis (Australia)</i>	Management of MPNs in special patient population <i>Prof. Norio Komatsu (Japan)</i>	First-Line Management of DLBCL: Challenges or Opportunities? <i>Prof. Mark Stephen Hertzberg (Australia)</i>	The unmet medical needs of immunomodulatory drug free regimens in relapsed myeloma <i>Prof. Evangelos Terpos (Greece)</i>
13:50-14:35	醫師會員演講(13) No.47-50 HSCT-3	HST 臨床試驗工作組報告 No.01-04	醫師會員演講(14) No.51-54 Benign disease	醫師會員演講(15) No.55-57 Acute leukemia-2

April 24 (Sunday)				
時間/講堂	第 201 會議室	第 401 會議室	第 205 會議室	第 301 會議室
14:35-15:20	全體學員請至第 401 會議室聽講	HST 臨床試驗工作組報告 No.05-08	全體學員請至第 401 會議室聽講	全體學員請至第 401 會議室聽講
15:20-16:05	Satellite Symposium (17) ^{諾華} Moderator: 高志平	請至第 201 會議室聽講	請至第 201 會議室聽講	請至第 201 會議室聽講
	Efficacy and Safety of Tisagenlecleucel in Adult Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Phase 2 ELARA Trial <i>Dr. Joaquin Martinez-Lopez (Spain)</i>			
16:05	中華民國血液及骨髓移植學會暨中華民國血液病學會聯合學術演講年會閉幕			

備註：

※發表者請事先準備 Power Point 簡報檔案，於發表前一個小時至試片處測試並繳交簡報檔案，以利會議順利進行。

※Keynote Speeches 及 Satellite Symposiums：每題 45 分鐘，其中包括 35 分鐘「演講」、10 分鐘「討論」。30 分鐘鈴響一聲，35 分鐘鈴響兩聲，請結束演講。

※醫師會員演講及 HST 臨床試驗工作組報告：每題 11 分鐘，其中包括 8 分鐘「演講」、3 分鐘「討論」。7 分鐘鈴響一聲，8 分鐘鈴響兩聲，請結束演講。

※護理會員演講：演講每題 12 分鐘，10 分鐘鈴響一聲，12 分鐘鈴響兩聲，請結束演講。每區間結束後將由主持人帶領綜合討論。

※壁報論文展示區：3 樓走廊。

※繼續教育學分：中華民國血液病學會、中華民國血液及骨髓移植學會、台灣內科醫學會、台灣兒科醫學會、中華民國癌症醫學會腫瘤內科、台灣癌症安寧緩和醫學會、台灣專科護理師學會(護理師/專科護理師)。

※午餐便當：全體會員可至 201、401 憑餐券領取餐點。



TBMT-HST 聯合學術年會演講題目、編號及時間細表(醫師部分)

April 23 (Saturday)			
時間/講堂	第 201 會議室	第 401 會議室	第 205 會議室
09:00	中華民國血液及骨髓移植學會暨中華民國血液病學會聯合學術年會開幕 (請會員直接至各會議室聽講)		
10:35-11:20	醫師會員演講(1) No. 01-04 Acute Leukemia-1 Moderator: 邱宗傑、侯信安	醫師會員演講(2) No. 05-07 Coagulation Moderator: 陳宇欽、周聖傑	醫師會員演講(3) No. 08-11 Pediatric hematology Moderator: 陳建旭、周獻堂
10:35-10:46	⁰¹ Utilizing Single Cell Analysis to Decipher the Epigenetic Perturbations in Acute Myeloid Leukemia 田豐銘/台北, 臺大醫院	⁰⁵ Endogenous VWF:Ag Level and Body Mass Index are Inverse Predictors of Annualized Bleeding Rate and Annualized Joint Bleeding Rate Respectively in Adults with Severe Haemophilia A with Episodic Treatment with rFVIII 張家堯/台北, 台北醫學大學附設醫院	⁰⁸ The Adherence to MRD Time Points Improves Treatment Outcomes of Childhood ALL in Taiwan: The Experience of TPOG-ALL-2013 Protocol 劉希哲/台北, 馬偕兒童醫院
10:46-10:57	⁰² Clinical Implications of Secondary-AML Type Mutations in Patients with De Novo Acute Myeloid Leukemia 孫國瑞/台北, 臺大醫院	⁰⁶ The Real-World Utility of PLASMIC Score in Thrombotic Thrombocytopenic Purpura 黃怡菁/台南, 成大醫院	⁰⁹ Characteristics and Outcomes of Second Cancers in Patients with Childhood Cancer: A Report from the Taiwan Pediatric Oncology Group 何宛玲/台北, 台北醫學大學附設醫院
10:57-11:08	⁰³ The Management of Rare Highly Aggressive Hematologic Disease: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) 邱倫璋/台北, 和信治癌中心醫院	⁰⁷ Clinical Features and Treatment Outcomes of Thrombosis with Thrombocytopenia Syndrome in a Single Medical Center 呂亭緯/台北, 臺大醫院	¹⁰ Donor Lymphocyte Infusion for Prophylaxis and Treatment of Relapse in Pediatric Hematological Malignancies after HSCT: A Single Institution Experience 侯明欣/台北, 台北榮民總醫院
11:08-11:19	⁰⁴ CD44 Expression in Bone Marrow Interstitial Fluid of Hematological Malignancies and Marrow Blasts 林芸孜/台南, 奇美醫院	/	¹¹ Advanced Management of Hepatic veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) in Pediatric Patients after Peripheral Blood Hematopoietic Stem Cell Transplantation 翁德甫/台中, 中山醫學大學附設醫院
11:20-12:05	醫師會員演講(4) No. 12-15 HSCT-1 Moderator: 高志平、邱世欣	醫師會員演講(5) No. 16-19 Lymphoma-1 Moderator: 姚明、高偉堯	醫師會員演講(6) No. 20-23 Myeloma Moderator: 黃聖懿、王銘崇
11:20-11:31	¹² Adding antithymocyte globulin decreases graft-versus host-disease after	¹⁶ Appraising FDG-PET Parameters Correlates Differentially with Two Types	²⁰ Risk Factors of Disease Progression after Front-line Autologous Stem Cell



April 23 (Saturday)			
時間/講堂	第 201 會議室	第 401 會議室	第 205 會議室
	haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide in children <i>巫康熙/台中，中山醫學大學附設醫院</i>	of Primary Thyroid Lymphoma <i>呂欣瑜/台北，臺大醫院</i>	Transplantation in Newly Diagnosed Multiple Myeloma <i>許德麟/台北，台北榮民總醫院</i>
11:31-11:42	¹³ Impact of CD34+ cell dose on neutrophil and platelet engraftment in autologous peripheral blood stem cell transplantation for lymphoma and myeloma <i>楊牧峻/台北，台北慈濟醫院</i>	¹⁷ Analyzing Bi-Lineage Composite Lymphoma & Lymphocyte Proliferative Disorder Using Next-Generation Sequencing of V(D)J Recombination <i>蔡明道/台北，臺大醫院</i>	²¹ Real-World Experience of Daratumumab in Multiple Myeloma from a Single Medical Center <i>洪郁欽/台北，臺大醫院</i>
11:42-11:53	¹⁴ Second Primary Malignancy after Hematopoietic Stem Cell Transplantation <i>譚傳德/台北，和信治癌中心醫院</i>	¹⁸ Successful Treatment of Bulky cardiac Lymphoma Complicated by Cardiac Tamponade Using Attenuated Immunochemotherapy (R-miniCHOP) in an Elderly Woman <i>楊騏毓/台北，振興醫院</i>	²² Levels of Vitamin D in patients with newly diagnosed multiple myeloma <i>林耘曲/台北，臺大醫院</i>
11:53-12:04	¹⁵ Pseudoallogeneic cytokine-induced NK/T cells for the treatment of relapse post allogeneic hematopoietic stem cell transplantation <i>葉士芃/台中，中國醫藥大學附設醫院</i>	¹⁹ Lenalidomide based therapy in relapse and refractory primary CNS lymphoma(rrPCNSL) - A single institute experience <i>廖浚凱/高雄，高雄長庚醫院</i>	²³ A Single-Center Experience of Post-ASCT Consolidation and Maintenance Therapy in Patients with Multiple Myeloma <i>黃千慈/高雄，高雄醫學大學附設醫院</i>
13:10-13:55	醫師會員演講(7) No. 24-27 HSCT-2 Moderator: 葉士芃、王博南	醫師會員演講(8) No. 28-31 MPN Moderator: 陳志丞、林建嶽	醫師會員演講(9) No. 32-35 Lymphoma-2 Moderator: 吳尚儒、黃威翰
13:10-13:21	²⁴ The Survival of Patients with Myelofibrosis Receiving Allogeneic Hematopoietic Stem Cell Transplantation: 10-Year Experience in Taipei Veteran General Hospital <i>唐振育/台北，台北榮民總醫院</i>	²⁸ Overall And Progression-Free Survival In Patients Treated With Fedratinib As First-Line Myelofibrosis Therapy And After Prior Ruxolitinib: Results From The Jakarta And Jakarta2 Trials <i>張正雄/彰化，彰濱秀傳紀念醫院</i>	³² Treatment Outcome of Orbital Marginal Zone B Cell Lymphoma -- Single Institution experience <i>譚傳德/台北，和信治癌中心醫院</i>
13:21-13:32	²⁵ Outcome of allogeneic stem cell transplantation for B-cell lymphoma in Taiwan <i>林子騫/台南，成大醫院</i>	²⁹ Comparison of the Molecular Responses and Outcomes between BCR-ABL1 e14a2 and e13a2 Transcripts in CML Patients Receiving Different Tyrosine Kinase Inhibitors <i>蘇羿圀/桃園，林口長庚醫</i>	³³ Peripheral blood cell-free DNA detection of MYD88 L265P mutation in Waldenstrom <i>蕭樑材/台北，台北榮民總醫院</i>



April 23 (Saturday)			
時間/講堂	第 201 會議室	第 401 會議室	第 205 會議室
		院	
13:32-13:43	²⁶ Prognostic Relevance of Measurable Residual Disease Status in AML Patients Prior to Allogeneic Stem Cell Transplantation 陳姿婷/台中，中國醫藥大學附設醫院	³⁰ Comparison of Clinical and Molecular Features between Patients with Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Presenting with Thrombocytosis in Taiwan 郭明宗/桃園，林口長庚醫院	³⁴ Clinical value of MYD88 L265P mutation in the cerebrospinal fluids of patients with primary and secondary central nervous system involvement of diffuse large B-cell lymphoma 蕭樑材/台北，台北榮民總醫院
13:43-13:54	²⁷ Outcome of Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation –Results from a Single-Center Observational Study 王閔宏/高雄，高雄醫學大學附設醫院	³¹ Clonal evolution in myeloproliferative neoplasm revealed by single-cell multi-omics analysis 林建鴻/台北，馬偕醫院	³⁵ Intravascular Large B-Cell Lymphoma Is Featured with Polyploidy and Poor Survival 蕭宇廷/台北，臺大醫院
13:55-14:40	醫師會員演講(10) No. 36-39 Translation research Moderator: 劉大智、胡淑惠	醫師會員演講(11) No. 40-43 BM failure syndrome Moderator: 劉俊煌、巫康熙	醫師會員演講(12) No. 44-46 Lymphoma-3 Moderator: 陳彩雲、黃泰中
13:55-14:06	³⁶ Characterization of Cellular Pathogenic Mechanism of Type 1 von Willebrand Disease with A1500V mutation 賴學緯/台北，三軍總醫院	⁴⁰ Mutation Allele Frequency Can Further Improve the Risk Stratification of WHO-defined MDS Patients 李婉瑄/台北，臺大醫院	⁴⁴ The discordance between the end-of-treatment PET imaging and survival improvement in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a single-institution experience 林益庭/台北，台北榮民總醫院
14:06-14:17	³⁷ Single-cell RNA Sequencing Analysis for Bone Marrow Stromal Cells to Explore the Mechanism of Mouse Myelofibrosis Induced by TPO Overexpression Plus IDH Mutation 林建崧/2021 年度麒麟青年研究發展獎成果報告	⁴¹ Oncogene SALL4 as a Potential Target in MDS Patients Treated with Hypomethylating Agents 劉耀中/2021 年度 Sysmex 精準醫學研究發展獎成果報告	⁴⁵ Treatment of Advance Stage Classical HL, Experience Sharing of a Single Institution, KCGMH 邱玲榕/高雄，高雄長庚醫院
14:17-14:28	³⁸ Electrical Modulation Protects Bone Marrow Microenvironment from Chemotherapy-Related Injury Through Adrenergic Signals 傅蓓安/台南，成大醫院	⁴² Higher RUNX1 Expression is Associated with Worse Prognosis in Myelodysplastic Syndrome Patients 姚啟元/台北，臺大醫院	⁴⁶ Primary breast lymphoma: A retrospective case-control study 鄧齡喬/台中，台中榮民總醫院



April 23 (Saturday)			
時間/講堂	第 201 會議室	第 401 會議室	第 205 會議室
14:28-14:39	³⁹ Telomere length measurement in different lineages of human leukocytes by using flow cytometry with fluorescent in situ hybridization (Flow-FISH) method 楊尚憲/花蓮，花蓮慈濟醫院	⁴³ Eltrombopag in Severe Aplastic Anemia: Linkou CGMH experience 蘇柏旭/基隆，基隆長庚醫院	

備註：

※發表者請事先準備 Power Point 簡報檔案，於發表前一個小時至試片處測試並繳交簡報檔案，以利會議順利進行。

※醫師會員演講及 HST 臨床試驗工作組報告：每題 11 分鐘，其中包括 8 分鐘「演講」、3 分鐘「討論」。7 分鐘鈴響一聲，8 分鐘鈴響兩聲，請結束演講。



TBMT-HST 聯合學術年會演講題目、編號及時間細表(醫師部分)

April 24 (Sunday)			
時間/講堂	第 201 會議室	第 205 會議室	第 301 會議室
13:50-14:35	醫師會員演講(13) No. 47-50 HSCT-3 Moderator: 李啟誠、滕傑林	醫師會員演講(14) No. 51-54 Benign disease Moderator: 張明志、張鴻	醫師會員演講(15) No. 55-57 Acute leukemia-2 Moderator: 高小雯、邱倫璋
13:50-14:01	⁴⁷ Using Deep Learning Algorithm Assess the Risk of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation <i>吳宜穎/台北，三軍總醫院</i>	⁵¹ A Comparison of Transfusion Reactions Between Prestorage and Poststorage Leukoreduced Apheresis Platelets: A Propensity-Score Matching Analysis <i>簡聖軒/台北，台北榮民總醫院</i>	⁵⁵ The Infectious Side Effect of Venetoclax Based Regimen in Acute Myeloid Leukemia: a Real-World Retrospective Analysis <i>高冠鈞/台北，台北榮民總醫院</i>
14:01-14:12	⁴⁸ Donor Specific Antibodies Were Associated with High Graft Failure and Desensitization Procedures Improved Engraftment in Patients Underwent Mismatched Allogeneic Stem Cell Transplantation <i>林育任/台北，臺大醫院</i>	⁵² A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of givosiran in patients with acute hepatic porphyrias (ENVISION): An analysis of the Taiwanese cohort <i>王建得/台中，台中榮民總醫院</i>	⁵⁶ Expression and Prognostic Value of Bone Marrow Cytokine Levels in Acute Myeloid Leukemia <i>陳睿哲/台北，臺大醫院</i>
14:12-14:23	⁴⁹ Machine Learning of Genomic Factors in 1,961 Patients with Acute Myeloid Leukemia Identifies Patients with Very Good or Very Poor Prognosis Who Do Not Benefit from Allogeneic Hematopoietic Cell Transplant in First Remission <i>羅昱諤/台北，臺大醫院</i>	⁵³ Clinical Experience of Deferasirox in Transfusion-dependent Anemia at a Single Institution <i>侯人尹/台北，馬偕兒童醫院</i>	⁵⁷ Prognosis factors in patients with bone marrow hemophagocytosis <i>蔣京谷/台北，台北榮民總醫院</i>
14:23-14:34	⁵⁰ Hematopoietic Stem Cell Transplantation in Patients with Severe Aplastic Anemia: A 33-year Experience	⁵⁴ Pathophysiology of Hepatitis C Virus-Associated Immune Thrombocytopenia: A Phenotype of Cryoglobulinemia <i>黃慈恩/嘉義，嘉義長庚醫院</i>	



	徐千富/台北，台北榮 民總醫院		
--	--------------------	--	--

備註：

※發表者請事先準備 Power Point 簡報檔案，於發表前一個小時至試片處測試並繳交簡報檔案，以利會議順利進行。

※醫師會員演講及 HST 臨床試驗工作組報告：每題 11 分鐘，其中包括 8 分鐘「演講」、3 分鐘「討論」。7 分鐘鈴響一聲，8 分鐘鈴響兩聲，請結束演講。